Tori Spelling says she used Mounjaro after her fifth child

Tori Spelling, 51, said on her podcast "misSPELLING" that she used Mounjaro, a drug approved for Type 2 diabetes, to lose weight she gained after having her fifth child, Beau, in 2017 ^[1][2]. She said the drug helped her lose about 40 pounds ^[1].

Mounjaro's active ingredient is tirzepatide, the same molecule sold under the brand name Zepbound when prescribed for weight loss ^[2]. Spelling did not say which version she used or whether her prescription was for diabetes or for weight management.

Spelling said she struggled to lose weight after Beau in a way she hadn't after her first four pregnancies. "At my heaviest, I was probably 120 pounds my entire life, and after Beau, I was 160. I couldn't lose the weight, and the doctor was like, 'Well, it's an age thing,'" she said; she was 44 at the time ^[1][2]. She said she tried eating more protein and intermittent fasting first, but "the weight wouldn't come off" ^[2].

According to Women's Health, Spelling said her doctor put her on Mounjaro at the same time as hormone therapy because she was approaching menopause: "She put me simultaneously with the hormones on Mounjaro," Spelling said ^[2]. She said she stopped taking Mounjaro at the end of January, once she reached what she called her "ideal weight." "I did go off of it because I had hit my ideal weight and I felt like I didn't want to get any thinner," she said ^[2].

Spelling also addressed why she's discussing the drug now after years of public scrutiny over her postpartum body. "I did Mounjaro, and everyone admits it now. It's a different time so I don't feel shamed saying that," she said ^[1].

Why it matters for patients

Spelling's account is a personal story, not a clinical report, and the sources do not say whether her prescription was for diabetes, for obesity, or for another reason, nor do they detail her dose or how long she used the drug before stopping ^[1][2]. Her account pairs tirzepatide with hormone therapy during a perimenopausal period, which she says her doctor recommended together ^[2]. The sources do not explain how those two treatments might interact, and readers who take a GLP-1 or dual GIP/GLP-1 drug alongside other medications may have questions that only their own prescriber's records can answer.

Spelling's disclosure also reflects a shift she describes in public attitudes: she said she feels less "shamed" discussing tirzepatide use now than she might have in the past ^[1]. Her story does not include information on side effects she experienced, cost, insurance coverage, or how quickly the weight loss occurred, so readers looking for that kind of detail will not find it in these sources.

Her comments add to a wider pattern of celebrities describing tirzepatide or semaglutide use tied to postpartum weight or hormonal transitions, though the sources here focus only on Spelling's specific account and do not compare it to other public figures' experiences in detail ^[1][2].

What happens next

The sources do not report any planned follow-up from Spelling on this topic beyond the original podcast episode and subsequent interviews summarized here ^[1][2]. No further medical, regulatory, or reporting developments tied to this disclosure are described in the available sources.